Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
18.83 USD | +1.18% | +0.64% | +30.58% |
04-29 | Piper Sandler Raiises Price Target on Organon to $24 From $22, Maintains Overweight Rating | MT |
04-09 | Morgan Stanley Lifts Price Target on Organon to $18 From $17, Keeps Equalweight Rating | MT |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- The company is one of the best yield companies with high dividend expectations.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- The company appears highly valued given the size of its balance sheet.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+30.58% | 4.79B | B | ||
+33.25% | 704B | C+ | ||
+28.59% | 577B | B | ||
-3.55% | 348B | C+ | ||
+18.16% | 327B | B- | ||
+4.36% | 288B | C+ | ||
+14.81% | 234B | B+ | ||
+4.93% | 198B | B- | ||
-9.78% | 194B | A+ | ||
-3.69% | 147B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- OGN Stock
- Ratings Organon & Co.